BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Novartis Oncology 



East Hanover  New Jersey    U.S.A.
Phone: 888-NOW-NOVA Fax:


SEARCH JOBS



When science and passion connect, innovation happens. The oncology community shares a common mission: to transform the way patients live with cancer and related diseases. At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients.

With over 9000 Oncology employees worldwide operating in 85 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to transforming the lives of patients living with cancer around the world. We have developed eight new practice-changing medicines in the past decade, addressing unmet medical needs in patients worldwide. Our broad pipeline includes over 25 new molecular entities in development, targeting key molecular pathways in cancer biology.

Visit Novartis.com to learn more about our group of companies

Connecting within the oncology community
Making connections in science and building relationships with people in the oncology community fuels our ability to deliver innovative medicines for patients. More than a decade ago, Novartis AG was the first company to form a dedicated global business unit for developing and launching innovative oncology medicines that address the unmet medical needs of patients. This early vision has led to one of the most dynamic portfolios of new products in the marketplace.

Turning scientific possibility into clinical reality
A decade of success in oncology drug development has taught us the value of our connections within the oncology community and their importance to innovation. Together, we explore novel compounds in clinical development, many with potential best-in-class status, aiming to advance or create new standards of care. Our strategy is composed of three elements:

Precision oncology accelerates development and improves results.
Collaboration leads to breakthroughs.
Patient-inspired solutions provide more than medicine.

Unique, dedicated global capabilities support our strategy.

At Novartis Oncology, we are a leader in driving the practice of precision oncology treatment. Learn about our viewpoint on achieving better patient outcomes.


 Key Statistics


Email:
Ownership: Public

Web Site: Novartis Oncology
Employees: 100,000
Symbol: NVS
 



Industry
Pharmaceutical






 Company News
Health Canada Approves Novartis Oncology (NVS)'s AFINITOR for Breast Cancer 1/16/2013 7:36:34 AM
ASA404 to Feature in Novartis Oncology (NVS) Pipeline Update and at San Antonio Breast Cancer Symposium 12/9/2009 10:30:49 AM
Newly Published Phase III Data Show Novartis Oncology (NVS) (JOBS) Drug Sandostatin(R) LAR Depot Reduced Risk of Disease Progression by 66% in Advanced NET Patients 10/1/2009 6:40:31 AM
Novartis Oncology (NVS): Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy(1, 2) 9/25/2009 11:07:39 AM
Novartis Oncology (NVS)'s Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5/8/2009 11:55:46 AM
Novartis Oncology (NVS) Release: Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women 4/30/2007 1:50:04 PM
NICE Initial Recommendation: One Step Closer To Backing Aromatase Inhibitor Treatment For Women With Early Breast Cancer 5/23/2006 11:25:33 AM
Novartis Oncology (NVS) Release: Femara Endorsed Post-Surgery For Women With Early Breast Cancer In Scotland...But Women In The Rest Of The UK Must Wait A Further 6 Months 5/8/2006 1:15:03 PM
Novartis Oncology (NVS) Release: New Clinical Data Show Dramatic Benefits Of Femara(R) For Women With Breast Cancer Even After Prolonged Period Of No Anti-Cancer Treatment 12/13/2005 12:22:24 PM
Novartis Oncology (NVS) Release: UK Leads Europe And US In Milestone Post-op Breast Cancer Treatment Decision 12/8/2005 11:06:48 AM
12